{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:15:45Z","timestamp":1786997745201,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.trim.2016.08.009","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T07:38:42Z","timestamp":1472801922000},"page":"46-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-3514","authenticated-orcid":false,"given":"Sarita Rani","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsuz","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sehrawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparno","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2016.08.009_bb0005","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0010","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","article-title":"How I treat refractory acute GVHD","volume":"109","author":"Deeg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.trim.2016.08.009_bb0015","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2012.04.006","article-title":"Secondary treatment of acute graft-versus-host disease: a critical review","volume":"18","author":"Martin","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/bbmt.2002.v8.pm11939605","article-title":"Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment","volume":"8","author":"Arai","year":"2002","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0025","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bmt.1703032","article-title":"Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin","volume":"27","author":"Khoury","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0030","doi-asserted-by":"crossref","unstructured":"Westin, J.R., Saliba, R.M., de, L.M., Alousi, A., Hosing, C., Qazilbash, M.H., Khouri, I.F., Shpall, E.J., Anderlini, P., Rondon, G., Andersson, B.S., Champlin, R., and Couriel, D.R., Steroid-refractory acute GVHD: predictors and outcomes. Adv. Hematol. 2011. 2011: 601953.","DOI":"10.1155\/2011\/601953"},{"key":"10.1016\/j.trim.2016.08.009_bb0035","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","article-title":"Cytokine dysregulation and acute graft-versus-host disease","volume":"80","author":"Antin","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.trim.2016.08.009_bb0040","doi-asserted-by":"crossref","first-page":"976793","DOI":"10.1155\/2011\/976793","article-title":"T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications","volume":"2011","author":"Briones","year":"2011","journal-title":"Bone Marrow Res."},{"key":"10.1016\/j.trim.2016.08.009_bb0045","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2174\/1381612043452569","article-title":"Anti-cytokine therapy for the treatment of graft-versus-host disease","volume":"10","author":"Jacobsohn","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.trim.2016.08.009_bb0050","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/bmt.2010.117","article-title":"Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD","volume":"46","author":"Rager","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0055","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MPH.0b013e31819daf60","article-title":"Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease","volume":"31","author":"Rao","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.trim.2016.08.009_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V95.1.83","article-title":"Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease","volume":"95","author":"Przepiorka","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.trim.2016.08.009_bb0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1705761","article-title":"Infliximab for GVHD therapy in children","volume":"40","author":"Sleight","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0070","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2141.2004.04856.x","article-title":"Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis","volume":"124","author":"Srinivasan","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2016.08.009_bb0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/bmt.2015.247","article-title":"The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD","volume":"51","author":"Nadeau","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0080","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.bmt.1703737","article-title":"Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"30","author":"Massenkeil","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0085","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJM199906033402202","article-title":"Transplantation of anergic histoincompatible bone marrow allografts","volume":"340","author":"Guinan","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2016.08.009_bb0090","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2013.09.003","article-title":"In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial","volume":"19","author":"Koura","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12724","article-title":"Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: the need to look beyond post-transplantation cyclophosphamide in younger children","author":"Jaiswal","year":"2016","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0100","article-title":"Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide","author":"Jaiswal","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2016.08.009_bb0105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12185-013-1426-5","article-title":"Paternal bone marrow infusion as salvage therapy for severe GVHD following maternal haploidentical transplantation resulting in biparental chimerism","volume":"98","author":"Jaiswal","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2016.08.009_bb0110","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/bmt.2015.50","article-title":"Pre-transplant sirolimus might improve the outcome of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide for patients with severe aplastic anemia","volume":"50","author":"Jaiswal","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbmt.2015.11.010","article-title":"Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with Fludarabine-, Busulfan-, and Melphalan-based conditioning","volume":"22","author":"Jaiswal","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0120","unstructured":"Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J., and Thomas, E.D., 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995. 15: 825\u2013828."},{"key":"10.1016\/j.trim.2016.08.009_bb0125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1399-3046.2012.01756.x","article-title":"Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Yang","year":"2012","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0130","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bmt.1705306","article-title":"Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist","volume":"37","author":"Funke","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbmt.2011.06.012","article-title":"Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment","volume":"18","author":"Xhaard","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0140","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00007890-199409150-00013","article-title":"CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers","volume":"58","author":"Wallace","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.08.009_bb0145","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1182\/blood.V83.12.3815.3815","article-title":"In vivo blockade of CD28\/CTLA4: B7\/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice","volume":"83","author":"Blazar","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.trim.2016.08.009_bb0150","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1681\/ASN.2009111109","article-title":"Five-year safety and efficacy of belatacept in renal transplantation","volume":"21","author":"Vincenti","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2016.08.009_bb0155","article-title":"Immunological effects in patients with steroid refractory GvHD following treatment with Basiliximab, a CD25 monoclonal antibody","author":"Chakupurakal","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.trim.2016.08.009_bb0160","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.4049\/jimmunol.1300830","article-title":"CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-beta","volume":"191","author":"Deppong","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.trim.2016.08.009_bb0165","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/ajt.13154","article-title":"Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade","volume":"15","author":"Pilat","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.08.009_bb0170","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1111\/ajt.12934","article-title":"Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer","volume":"14","author":"Singh","year":"2014","journal-title":"Am. J. Transplant."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327416300910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327416300910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:35:26Z","timestamp":1601044526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327416300910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":34,"alternative-id":["S0966327416300910"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2016.08.009","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2016.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}